Management of HCV and HIV infections among people who inject drugs.
about
CCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug usersEligibility of persons who inject drugs for treatment of hepatitis C virus infection.Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners.Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.Does ART prevent HIV transmission among MSM?Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levelsCohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response.Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study.Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers.Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection.Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting.Understanding decisions made about hepatitis C treatment by couples who inject drugs.Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Predictors of accessing antiretroviral therapy among HIV-positive drug users in China's National Methadone Maintenance Treatment Programme.Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care.Lower life expectancy among people with an HCV notification: a population-based linkage study.Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents.Recommendations for the management of hepatitis C virus infection among people who inject drugs.The Second Canadian Symposium on hepatitis C virus: a call to action.The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.'Not just methadone Tracy': transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings.Detecting spatial clusters of HIV and hepatitis coinfectionsHepatitis C infection substantially reduces survival of alcohol-dependent patients
P2860
Q28534869-49D166ED-CC26-4F5B-B917-98074D8BD4C3Q30429470-DA16F53B-313A-49AD-8E12-B5F998541277Q33795847-CD8EA407-994B-40AC-8D5F-4F9C889CB0E3Q33802414-51D91491-3642-4C0C-99D3-0BCFE04D6079Q35105946-153B7B78-909E-4814-A723-DCA1F50A2D6DQ36137527-B0699E36-1318-427A-BAFF-D22B7959DC9AQ36403679-4DEF7822-7917-4118-8A94-A23866398ECBQ36590782-7867C45A-D67F-463A-B698-08E557334D40Q37460833-16678EC5-E672-499C-AFD2-FB5FCEDA03E4Q37512411-542E15BF-563A-40F1-9777-1172D9036065Q37701782-928C646D-36F7-4BF9-A1C9-DEB110BC0BE2Q38064495-8C063247-F868-4B93-99C1-9E2FC19B91ADQ38123945-0E643306-B3B2-4D12-9C28-8791D8B1E9A6Q38123947-BE39BD3A-E9A6-4062-842A-EE3ACF001FCEQ39407573-ED909EC5-85D5-4D85-AA07-FF13AA1A8627Q40608969-55795535-C3B6-44E1-8683-2D7BF8ECE3EEQ40641871-7B9FA940-7FE2-4FD2-A4E9-B5C7ABBBE38CQ40775611-16B32A4E-A4D7-41CE-871D-518967790855Q40959924-F1E7CF93-132E-4E8D-8577-DD73EB7616A8Q41047662-0E4F6E6D-EBAE-4275-A3C5-0E4A31E1CD58Q41187933-A06EFB3E-9FA5-4AEF-96F2-59EC18CC4EB1Q41496602-0E287E9C-ACE3-48F6-A403-D015C27FCF86Q42218829-37684EEF-965A-4D56-99E8-30F1FD54599AQ42251464-0799BF23-2D77-4543-9520-673E03835961Q42259402-CC97D299-79F5-45D3-A340-C738F7B260F5Q42280296-DE8BE3A8-387F-460A-88CB-4E02CA1B3D29Q42922380-0047F780-342D-43BB-8614-6631890FC795Q42955909-9A4616E1-EF91-4540-9EC5-A2754AB28661Q44105883-D5B06226-5BDB-4F52-B1F7-5617DC6CDBD4Q52304388-305535AB-A100-4814-9B2F-D996F45C7796Q58727324-DF39A563-7971-4584-837F-959E7EDEED61Q58806322-C2055149-8B52-4080-873B-0197C2BC6D64
P2860
Management of HCV and HIV infections among people who inject drugs.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Management of HCV and HIV infections among people who inject drugs.
@en
Management of HCV and HIV infections among people who inject drugs.
@nl
type
label
Management of HCV and HIV infections among people who inject drugs.
@en
Management of HCV and HIV infections among people who inject drugs.
@nl
prefLabel
Management of HCV and HIV infections among people who inject drugs.
@en
Management of HCV and HIV infections among people who inject drugs.
@nl
P1476
Management of HCV and HIV infections among people who inject drugs.
@en
P2093
Jason Grebely
Mark W Tyndall
P304
P356
10.1097/COH.0B013E32834BCB36
P577
2011-11-01T00:00:00Z